As rates of pancreatic and breast cancer increase among the population, Cannabis Bioscience International Holdings (OTC:CBIH) is addressing the situation with new treatment methodologies. The Houston-based company submitted its inaugural pair of patents, targeting those with breast and pancreatic cancers for legal review and subsequent registration.

Why It Matters

These two cancers affect millions globally. Breast cancer impacts roughly one in eight women in the U.S. and pancreatic cancer is notorious for its late-stage diagnosis and grim prognosis, with a five-year survival rate below 10%.

"Given the stark statistics associated with these cancers, our team recognizes the critical need for aggressive yet targeted interventions," said Jennifer Salguero, PhD in Science with emphasis on Microbiology. "We aim to not only target the tumors but also safeguard surrounding tissues, leveraging the inherent anti-tumor properties of cannabinoids."

Read Also: Study Discovers Medical Cannabis Drives 6x Improvement In Killing Breast Cancer Cells

What's Next

CBIH said on Monday that it plans to "accelerate our pace of innovation... harnessing the antiviral, anti-inflammatory, and neuroprotective benefits of cannabinoids."

How? The company said it would submit an additional 3 to 4 patents per month throughout the remainder of the year, with a focus on patents that could help those with herpes zoster, knee osteoarthritis and Alzheimer's disease.

The company will also boost its research team given its focus on patent and formulation development. CBIH welcomed an expert in biology, pharmaceutical chemistry, public health, and dermatic cosmetics, Sheila Tarqui, to its ranks.

Additionally, the company is recruiting medical specialists in oncology and cardiology to develop other innovative treatments.

"These strategies contribute to securing and protecting our intellectual property which is paramount. By harnessing cutting-edge therapies, artificial intelligence, and advanced biotechnological techniques, we aim to safeguard and successfully market our groundbreaking medical advancements," said Rosangel Andrades, research and development department director.

Read Next

• Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods

To learn more about innovation in cannabis, come join us at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.